RE:Retinol market sizeLet's include Botox with an opinion by Bard:
Sirona Biochem's GlycoProteMim™ is a novel anti-aging molecule that has the potential to be a viable alternative to Botox. Both GlycoProteMim™ and Botox are used to address the signs of aging, such as wrinkles and fine lines. However, they work in different ways.
Botulinum toxin, the active ingredient in Botox, is a neurotoxin that temporarily paralyzes muscles, thereby reducing the appearance of wrinkles. GlycoProteMim™, on the other hand, is a naturally occurring protein that stimulates the production of collagen and hyaluronic acid, which are essential for youthful skin.
Based on its safety profile and long-lasting effects, GlycoProteMim™ could be a promising alternative to Botox for many consumers. However, more research is needed to compare the efficacy of the two products in a head-to-head trial.
The global Botox market is estimated to be worth $6.1 billion in 2023. This market is expected to grow at a CAGR of 5.5% from 2023 to 2028, reaching $8.2 billion by 2028. The growth of this market is driven by the increasing demand for aesthetic procedures, the aging population, and the rising disposable incomes of consumers in emerging markets.